Patent · US Active

Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin

US10434167B2 · kind B2 · utility

0Cited by

24References

16Claims

0Family size

Assignee

The Government of the United States, as represented by the Secretary of the Army · US

Inventors

Carl R. Alving · Bethesda, US
Zoltan Beck · Rockville, US

Key dates

Filing date	Mar 25, 2015
Grant date	Oct 8, 2019
Priority date	—
Expiry date	Mar 25, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16171
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein is an adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition to saponin (e.g., QS-21), wherein the liposome composition comprises i) a lipid bilayer comprising phospholipids in which the hydrocarbon chains have a melting temperature in water of ≥23° C. and ii) cholesterol at a mole percent concentration of greater than about 50% (mol/mol), preferably about 55% to about 71% (mol/mol), or more preferably about 55% (mol/mol). The adjuvant formulation displays minimal toxicity of either lipid A or saponin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.